This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Maintenance Effect of Clobex Shampoo on Subjects With Moderate to Severe Scalp Psoriasis

This study has been completed.
Information provided by:
Galderma Identifier:
First received: November 16, 2006
Last updated: May 28, 2008
Last verified: May 2008
The objective of the study is to assess the maintenance effect on scalp psoriasis of Clobex® Shampoo 0.05% when used twice weekly.

Condition Intervention Phase
Scalp Psoriasis Drug: Clobex Shampoo 0.05% Drug: clobex shampoo placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparison of the Maintenance Effect of Clobex® Shampoo 0.05% Used Twice Weekly vs. Vehicle on Scalp Psoriasis in Subjects Who Successfully Responded to a 4-Week Daily Course of Clobex® Shampoo 0.05%

Resource links provided by NLM:

Further study details as provided by Galderma:

Primary Outcome Measures:
  • Global severity score [ Time Frame: 1st relapse ]

Secondary Outcome Measures:
  • Safety [ Time Frame: all visits ]
  • Quality of Life [ Time Frame: end of study phases ]

Enrollment: 288
Study Start Date: September 2006
Study Completion Date: August 2007
Arms Assigned Interventions
Experimental: 1 Drug: Clobex Shampoo 0.05%
twice weekly
Placebo Comparator: 2 Drug: clobex shampoo placebo
twice weekly

Detailed Description:

Psoriasis is a chronic disease that affects the skin, the scalp and joints. Scalp psoriasis is very common and can have an important impact on people's life.

Primary objective of scalp psoriasis treatments is to gain initial and rapid control of the disease process with a minimum of side-effects and improve patient quality of life.

Still, one of the unmet needs of scalp psoriasis therapies is the maintenance of a long-term remission. For corticosteroids in particular, one of the drawbacks is the disease recurrences after cessation of the treatment.

Therefore the establishment of a modified corticosteroid dosing regimen that would allow remission with minimal side-effects is suitable.

The purpose of this study is to assess how long a patient can be successfully maintained in a good condition when using Clobex® shampoo only twice a week.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female subjects aged 18 years or older.
  • Subjects with moderate to severe scalp psoriasis

Exclusion Criteria:

  • Subjects who need systemic treatment for their body psoriasis
  • Subjects with a washout period for topical treatment(s) on the scalp less than:

    • Corticosteroids 2 weeks
    • All other anti-psoriasis medications 2 weeks
  • Subjects with a washout period for systemic treatment(s) less than:

    • PUVA therapy 4 weeks
    • Biological therapies 12 weeks
    • Treatments other than biologicals with a possible efficacy on psoriasis 4 weeks
    • Treatment known to worsen psoriasis 2 weeks
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00400725

centre de Recherche Dermatologique du Québec
Quebec, Canada
Sponsors and Collaborators
Principal Investigator: Poulin, MD Centre de Recherche Dermatologique du Quebec Métropolitain
  More Information

Additional Information: Identifier: NCT00400725     History of Changes
Other Study ID Numbers: RD.03.SPR.29060
Study First Received: November 16, 2006
Last Updated: May 28, 2008

Keywords provided by Galderma:
scalp psoriasis

Additional relevant MeSH terms:
Skin Diseases, Papulosquamous
Skin Diseases
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on August 22, 2017